Physician profile

Daniel Porter Barnes

Urology · Oklahoma City, OK

NPI 1861429052

$6,619.96

in general payments reported to CMS, 2019-2025

45 companies · $1,082 in 2025

The $1,082 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,044.77
Education$23.93

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $1,461.51 2019-2025 Xtandi, Myrbetriq, Veozah
Abbvie INC. $1,403.05 2019-2025 Lupron Depot, Botox
Pfizer INC. $718.68 2019-2025
Myriad Genetic Laboratories, INC. $253.95 2020-2024 Prolaris
Sumitomo Pharma America, INC. $243.33 2023-2025 Orgovyx, Gemtesa
Janssen Biotech, INC. $229.24 2022-2025 Erleada
Blue Earth Diagnostics $194.64 2019-2025 Posluma
Merck Sharp & Dohme LLC $191.15 2022-2025 Keytruda, Keytruda Qlex, Lynparza
Myovant Sciences INC. $166.03 2021-2022
Endo Pharmaceuticals INC. $162.87 2020-2023 Xiaflex
Antares Pharma, INC. $154.62 2019-2024 Xyosted, Tlando, Nocdurna
Verity Pharmaceuticals INC. $154.42 2024-2025 Trelstar
Boston Scientific Corporation $134.50 2019-2024 Rezum Generator, Spaceoar Vue System - 10ml
Dendreon Pharmaceuticals LLC $99.43 2019-2025 Provenge
Travere Therapeutics, INC. $77.69 2019-2021
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Tolmar Pharmaceuticals, INC. $76.66 2019-2022
Bayer Healthcare Pharmaceuticals INC. $73.32 2020-2025
Urovant Sciences INC $60.03 2022
Endo USA, INC. $58.25 2024-2025 Xiaflex
Accord Healthcare, INC. $46.89 2023-2025
Cook Medical LLC $46.31 2020-2021
Allergan, INC. $46.03 2020-2021
Progenics Pharmaceuticals, INC. $38.53 2024-2025
Ambu INC. $38.25 2020-2023
Medtronic, INC. $37.88 2022
Ferring Pharmaceuticals INC. $37.85 2025 Adstiladrin
Urogen Pharma, INC. $36.32 2025
Halozyme INC $33.22 2023
Sun Pharmaceutical Industries INC. $32.01 2022
Clarus Therapeutics INC. $31.15 2021
Zyla Life Sciences, INC. $29.07 2019
Novartis Pharmaceuticals Corporation $27.53 2025
Innovation Technologies INC $24.09 2025 Irrisept
Bioprotect Medical, INC. $22.98 2025 Bioprotect Balloon Implant System
Trevena, INC. $19.04 2021
Vertex Pharmaceuticals Incorporated $18.43 2025
Mission Pharmacal Company $18.17 2019
Tolmar, INC. $17.68 2023
Hollister Incorporated $16.91 2022
Teleflex LLC $16.66 2021
Azurity Pharmaceuticals, INC. $15.01 2025 Azmiro
Coloplast Corp $14.71 2022
Olympus America INC. $14.38 2025 Itind System
Novo Nordisk INC $14.04 2025 Rivfloza
Laborie Medical Technologies Corp. $13.45 2024 Optilume Bph Drug Coated Balloon Catheter

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel Porter Barnes

$6,619.96

in general payments reported 2019-2025

Years
2019-2025
Top company
Astellas Pharma US INC
Context
The $1,082 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

https://glasscript.com/doctor/175647/daniel-porter-barnes

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.